This company has been marked as potentially delisted and may not be actively trading. Centogene (CNTG) News Today Add Compare Share Share Headlines Stock AnalysisBuy This Stock CNTG Latest News All Sources Trusted Sources MarketBeat Barchart Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent September 2025 August 2025 July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 Time Period CENTOGENE Closes Strategic Transaction with Private Equity Group Charme Capital PartnersMarch 12, 2025 | globenewswire.comCENTOGENE Announces Voting Results of Extraordinary General MeetingDecember 4, 2024 | globenewswire.comCENTOGENE Signs Strategic Transaction With Private Equity Group Charme Capital PartnersNovember 13, 2024 | globenewswire.comCENTOGENE Data on Novel Genetic Risk Factor for Parkinson’s Disease in The Lancet NeurologySeptember 26, 2024 | finance.yahoo.comCENTOGENE Data on Novel Genetic Risk Factor for Parkinson's Disease in The Lancet NeurologySeptember 25, 2024 | globenewswire.comCNTGF Centogene N.V.September 7, 2024 | seekingalpha.comCentogene N.V. (CNTG)August 21, 2024 | finance.yahoo.comCentogene B V (CNTGF)August 15, 2024 | investing.comCENTOGENE Receives Delisting Notice From NasdaqAugust 7, 2024 | globenewswire.comCENTOGENE Publication in Brain Journal Reveals 15% of Parkinson’s Disease Cases Are Linked to Genetic FactorsAugust 2, 2024 | markets.businessinsider.comCENTOGENE Publication in Brain Journal Reveals 15% of Parkinson's Disease Cases Are Linked to Genetic FactorsAugust 1, 2024 | globenewswire.comC-Path and CENTOGENE MOU to Enhance Collaboration in Lysosomal Disease Research and Drug DevelopmentJune 20, 2024 | globenewswire.comCENTOGENE Announces Adoption of All Resolutions Tabled at 2024 Annual General MeetingMay 31, 2024 | globenewswire.comCENTOGENE Reports Full Year 2023 Financial Results and Recent Business HighlightsMay 15, 2024 | globenewswire.comCENTOGENE Secures Approx. $20 Million to Strengthen Cash PositionMay 15, 2024 | globenewswire.comCENTOGENE and Evotec Discover Promising New Molecule to Treat Gaucher DiseaseMay 14, 2024 | globenewswire.comCentogene NV: CENTOGENE Biodatabank Grows to Incorporate Disease Insights From Over 850,000 Diverse PatientsMay 10, 2024 | finanznachrichten.deCENTOGENE Biodatabank Grows to Incorporate Disease Insights From Over 850,000 Diverse PatientsMay 10, 2024 | globenewswire.comCentogene faces Nasdaq delisting over share priceApril 4, 2024 | investing.comCENTOGENE Receives Nasdaq Non-Compliance NoticeApril 2, 2024 | globenewswire.comCentogene (NASDAQ: CNTG)March 22, 2024 | fool.comCENTOGENE Extends Strategic Partnership With Takeda to Continue Providing Access to Genetic Testing for Patients With Lysosomal Storage DisordersMarch 19, 2024 | globenewswire.comCentogene NV: CENTOGENE Collaborates on Research Published in Science Showing Immunopathological Landscape of Human Pre-TCRa DeficiencyMarch 1, 2024 | finanznachrichten.deCENTOGENE scopre la carenza del recettore alfa delle cellule pre-TFebruary 29, 2024 | it.investing.comCENTOGENE Collaborates on Research Published in Science Showing Immunopathological Landscape of Human Pre-TCRα DeficiencyFebruary 29, 2024 | globenewswire.comCentogene NV: CENTOGENE Explores Strategic AlternativesFebruary 28, 2024 | finanznachrichten.deCentogene NV: CENTOGENE Announces Receipt of Nasdaq Notice of Delisting and Intention to Request a HearingFebruary 28, 2024 | finanznachrichten.deCentogene Explores Strategic Alternatives, Incl. SaleFebruary 28, 2024 | markets.businessinsider.comCentogene Announces Receipt Of Nasdaq Notice Of DelistingFebruary 28, 2024 | markets.businessinsider.comCentogene to explores strategic alternatives, gets Nasdaq delisting notice; shares plungeFebruary 28, 2024 | msn.comCENTOGENE Announces Receipt of Nasdaq Notice of Delisting and Intention to Request a HearingFebruary 28, 2024 | globenewswire.comCENTOGENE Explores Strategic AlternativesFebruary 28, 2024 | globenewswire.comCentogene NV: CENTOGENE and the Laboratory of Human Genetics of Infectious Diseases at Institut Imagine Announce Rare Disease Research CollaborationJanuary 25, 2024 | finanznachrichten.deCENTOGENE and the Laboratory of Human Genetics of Infectious Diseases at Institut Imagine Announce Rare Disease Research CollaborationJanuary 25, 2024 | finance.yahoo.comCentogene NV: CENTOGENE Receives French Research Tax Credit AccreditationJanuary 24, 2024 | finanznachrichten.deCENTOGENE and The Michael J. Fox Foundation Announce Research Project to Validate Genetic Risk Factors of Parkinson’s Disease Using MultiomicsJanuary 23, 2024 | finance.yahoo.comCENTOGENE Announces Preliminary Full Year 2023 RevenueJanuary 18, 2024 | finance.yahoo.comCentogene NV Ordinary Shares CNTGDecember 20, 2023 | morningstar.comMCentogene NV: CENTOGENE's Frontotemporal Dementia (FTD) Genetic Study, EFRONT, Reaches Initial Patient Enrollment MilestoneDecember 13, 2023 | finanznachrichten.deMotus GI, C4 Therapeutics among healthcare moversDecember 13, 2023 | msn.comCCCC, XPOF and AUVI are among pre market gainersDecember 13, 2023 | msn.comCENTOGENE’s Frontotemporal Dementia (FTD) Genetic Study, EFRONT, Reaches Initial Patient Enrollment MilestoneDecember 13, 2023 | finance.yahoo.comCentogene NV: CENTOGENE and Lifera, a Public Investment Fund (PIF) Company, Complete Strategic Joint Venture TransactionNovember 28, 2023 | finanznachrichten.deCENTOGENE and Lifera, a Public Investment Fund (PIF) Company, Complete Strategic Joint Venture TransactionNovember 28, 2023 | finance.yahoo.comEVER, BIVI and CNTG among mid-day moversOctober 31, 2023 | msn.comH.C. Wainwright Keeps Their Buy Rating on Centogene NV (CNTG)September 15, 2023 | markets.businessinsider.comCENTOGENE to Present at H.C. Wainwright 25th Annual Global Investment ConferenceSeptember 11, 2023 | finance.yahoo.comCENTOGENE Reports First Half 2023 Financial ResultsSeptember 7, 2023 | benzinga.comCentogene NV: CENTOGENE Receives Nasdaq Non-Compliance Notification Regarding Minimum Market Value of Publicly Held Shares DeficiencySeptember 1, 2023 | finanznachrichten.deCENTOGENE Announces Publication Establishing Lyso-Gb1 as a Predictive Biomarker for Gaucher Disease PatientsSeptember 1, 2023 | finance.yahoo.com Get Centogene News Delivered to You Automatically Sign up to receive the latest news and ratings for CNTG and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. CNTG Media Mentions By Week CNTG Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. CNTG News Sentiment▼0.000.73▲Average Medical News Sentiment CNTG News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. CNTG Articles This Week▼00▲CNTG Articles Average Week Get the Latest News and Ratings for CNTG and Related Stocks Enter your email address to receive the latest news and analysts' ratings for Centogene and its competitors. Sign Up View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. Related Companies and Tools Related Companies CCM News MGRX News MRAI News BRTX News BGLC News SSY News KDLY News ACON News NIVF News OTRK News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:CNTG) was last updated on 9/23/2025 by MarketBeat.com Staff From Our PartnersTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredTrump’s Plan May Undo 1933’s Biggest Financial InjusticeTrump's Reset Can Give Birth To America's Greatest Era Yet A 90-Year cycle may end soon, creating real weal...American Hartford Gold | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...Crypto 101 Media | SponsoredStunning new initiative unfolding in the White House?what I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredCapital Gains Tax Strategies for SeniorsCapital gains taxes can take a bite out of your retirement income—unless you have a smart strategy. From holdi...SmartAsset | SponsoredA New Way to Double Your Retirement Income?Bloomberg reports that a new class of investments is “entering a golden era,” with yields fueling a retail boo...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Centogene Please log in to your account or sign up in order to add this asset to your watchlist. Share Centogene With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free CNTG Stock Alerts